TW202444423A - 抗cdh6抗體-藥物結合物與vegf抑制劑之組合 - Google Patents

抗cdh6抗體-藥物結合物與vegf抑制劑之組合 Download PDF

Info

Publication number
TW202444423A
TW202444423A TW113109250A TW113109250A TW202444423A TW 202444423 A TW202444423 A TW 202444423A TW 113109250 A TW113109250 A TW 113109250A TW 113109250 A TW113109250 A TW 113109250A TW 202444423 A TW202444423 A TW 202444423A
Authority
TW
Taiwan
Prior art keywords
antibody
amino acid
acid sequence
cancer
cdh6
Prior art date
Application number
TW113109250A
Other languages
English (en)
Chinese (zh)
Inventor
長瀨翔太郎
Original Assignee
日商第一三共股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 日商第一三共股份有限公司 filed Critical 日商第一三共股份有限公司
Publication of TW202444423A publication Critical patent/TW202444423A/zh

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4738Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/02Linear peptides containing at least one abnormal peptide link

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
TW113109250A 2023-03-14 2024-03-13 抗cdh6抗體-藥物結合物與vegf抑制劑之組合 TW202444423A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2023-039600 2023-03-14
JP2023039600 2023-03-14

Publications (1)

Publication Number Publication Date
TW202444423A true TW202444423A (zh) 2024-11-16

Family

ID=92755258

Family Applications (1)

Application Number Title Priority Date Filing Date
TW113109250A TW202444423A (zh) 2023-03-14 2024-03-13 抗cdh6抗體-藥物結合物與vegf抑制劑之組合

Country Status (7)

Country Link
JP (1) JPWO2024190815A1 (enExample)
KR (1) KR20250170141A (enExample)
CN (1) CN120813389A (enExample)
AU (1) AU2024236246A1 (enExample)
MX (1) MX2025010805A (enExample)
TW (1) TW202444423A (enExample)
WO (1) WO2024190815A1 (enExample)

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
DK0590058T3 (da) 1991-06-14 2004-03-29 Genentech Inc Humaniseret heregulin-antistof
PT1071700E (pt) 1998-04-20 2010-04-23 Glycart Biotechnology Ag Modificação por glicosilação de anticorpos para melhorar a citotoxicidade celular dependente de anticorpos
EP2278003B2 (en) 1999-04-09 2020-08-05 Kyowa Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
EA013563B1 (ru) 2000-10-06 2010-06-30 Киова Хакко Кирин Ко., Лтд. Трансгенное животное, продуцирующее антитела с измененными углеводными цепями, способ получения антител и содержащее антитела лекарственное средство
EP2001358B1 (en) 2006-03-27 2016-07-13 University Of Maryland, Baltimore Glycoprotein synthesis and remodeling by enzymatic transglycosylation
EP2812442B9 (en) 2012-02-10 2023-02-15 University of Maryland, Baltimore Chemoenzymatic glycoengineering of antibodies and fc fragments thereof
CN104755494B (zh) 2012-10-11 2018-09-07 第一三共株式会社 抗体-药物偶联物
HRP20190056T1 (hr) 2013-12-25 2019-02-22 Daiichi Sankyo Company, Limited Konjugat anti-trop2 antitijelo-lijek
SMT202500030T1 (it) 2014-01-31 2025-03-12 Daiichi Sankyo Co Ltd Coniugato anticorpo anti-her2-farmaco
DK3129063T3 (da) 2014-04-10 2021-04-06 Daiichi Sankyo Co Ltd Anti-her3-antistof-lægemiddelkonjugat
BR112019012847A2 (pt) 2017-01-17 2019-12-10 Daiichi Sankyo Co Ltd anticorpo ou fragmento funcional do anticorpo, polinucleotídeo, vetor de expressão, células hospedeiras, método para produção de um anticorpo de interesse ou de um fragmento funcional do anticorpo e para produção de um conjugado de anticorpo-fármaco, conjugado de anticorpo-fármaco, composição farmacêutica, fármaco antitumoral, e, método de tratamento de um tumor.
TW202532101A (zh) 2017-05-15 2025-08-16 日商第一三共股份有限公司 抗體-藥物結合物及其用途
US11945882B2 (en) 2017-08-31 2024-04-02 Daiichi Sankyo Company, Limited Method for producing antibody-drug conjugate
EP3834843A4 (en) * 2018-08-06 2022-05-11 Daiichi Sankyo Company, Limited COMBINATION OF ANTIBODY-DRUG CONJUGATE AND TUBULIN INHIBITOR
EA202191641A1 (ru) * 2018-12-11 2021-09-13 Дайити Санкио Компани, Лимитед Комбинация конъюгата антитело-лекарственное средство с ингибитором parp
BR112021011894A2 (pt) * 2018-12-21 2021-09-08 Daiichi Sankyo Company, Limited Composição farmacêutica
KR20220152318A (ko) * 2020-03-12 2022-11-15 도레이 카부시키가이샤 암의 치료 및/또는 예방을 위한 의약품
EP4444360A1 (en) 2021-12-10 2024-10-16 Multitude Therapeutics Inc. Anti-cdh6 antibodies and antibody-drug conjugates thereof
WO2023102875A1 (en) 2021-12-10 2023-06-15 Multitude Therapeutics Inc. Anti-cdh6 antibody drug conjugate

Also Published As

Publication number Publication date
MX2025010805A (es) 2025-11-03
CN120813389A (zh) 2025-10-17
JPWO2024190815A1 (enExample) 2024-09-19
AU2024236246A1 (en) 2025-10-30
WO2024190815A1 (ja) 2024-09-19
KR20250170141A (ko) 2025-12-04

Similar Documents

Publication Publication Date Title
KR101941758B1 (ko) 항 trop2 항체-약물 컨쥬게이트
JP7458981B2 (ja) 抗体-薬物コンジュゲートとチューブリン阻害剤の組み合わせ
JP7769032B2 (ja) 抗体-薬物コンジュゲート投与による転移性脳腫瘍の治療
AU2019396895A1 (en) Combination of antibody-drug conjugate with PARP inhibitor
US20230414778A1 (en) COMBINATION OF ANTIBODY-DRUG CONJUGATE WITH ANTI-SIRPalpha ANTIBODY
KR20230041023A (ko) 항체-약물 콘주게이트의 제조 방법
TW202216207A (zh) 抗體-藥物結合物及cdk9抑制劑之組合
JP2025517656A (ja) 腫瘍抗原に特異的である抗体と、cd47阻害剤との組合せ
TW202444423A (zh) 抗cdh6抗體-藥物結合物與vegf抑制劑之組合
TW202444427A (zh) 抗CDH6抗體-藥物結合物與HIF-2α抑制劑之組合
TW202446421A (zh) 抗b7-h3抗體-藥物結合物與atr抑制劑或atm抑制劑之組合
KR102905497B1 (ko) 항체-약물 컨쥬게이트와 parp 저해제의 조합
HK40093327A (en) Combination of antibody-drug conjugate with anti-sirpalpha antibody
TW202216214A (zh) 抗her2抗體-藥物結合物與her二聚化抑制劑的組合
HK40064358A (en) Combination of antibody-drug conjugate with parp inhibitor
HK40045208A (en) Treatment of metastatic brain tumor by administration of antibody-drug conjugate